$9.55
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (PBYI) Q2 2026 Earnings Call Transcript
Is Puma Biotechnology (PBYI) a Great Value Stock Right Now?
Overview
52-week range
$4.30
$9.74
97% of range
Avg surprise (last 3)
+269.6%
Avg reaction (last 2)
+0.1%
50% positive
Latest IV / EM
30%
EM ±4.7% · $10 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.16 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.07 | $-0.17 | +58.8% | -216.7% | -2.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $0.17 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $0.12 | $0.08 | +50.0% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.06 | $-0.01 | +700.0% | — | +2.7% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $0.41 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.10 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.12 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.05 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $0.03 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $57M | $45M | — | $54M | $52M | $46M | — | $81M |
| Cost of revenue | $12M | $10M | — | $12M | $12M | $11M | — | $29M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $8M | $-4M | — | $10M | $7M | $4M | — | $22M |
| Net income | $8M | $-4M | — | $9M | $6M | $3M | — | $20M |
| EPS (diluted) | $0.16 | $-0.07 | — | $0.17 | $0.12 | $0.06 | — | $0.41 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $37M | $36M | $30M | $54M | $55M | $63M | $69M | $67M |
| Inventory | $13M | $9M | $6M | $9M | $9M | $9M | $9M | $3M |
| Total current assets | $145M | $142M | $163M | $144M | $137M | $133M | $148M | $157M |
| Total assets | $193M | $193M | $216M | $203M | $195M | $196M | $213M | $221M |
| Long-term debt | $0 | $0 | — | $0 | $11M | $11M | $22M | $33M |
| Total liabilities | $54M | $64M | $86M | $88M | $90M | $99M | $121M | $150M |
| Total equity | $139M | $128M | $130M | $115M | $105M | $97M | $92M | $71M |